BlackRock’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.55B | Buy |
4,181,432
+240,976
| +6% | +$72M | 0.02% | 535 |
|
|
2026
Q1 | $1.02B | Buy |
3,940,456
+2,639
| +0.1% | +$702K | 0.02% | 688 |
|
|
2025
Q4 | $971M | Buy |
3,937,817
+103,689
| +3% | +$21.8M | 0.02% | 699 |
|
|
2025
Q3 | $677M | Sell |
3,834,128
-11,027
| -0.3% | -$1.65M | 0.01% | 890 |
|
|
2025
Q2 | $529M | Sell |
3,845,155
-98,010
| -2% | -$14.4M | 0.01% | 1018 |
|
|
2025
Q1 | $711M | Sell |
3,943,165
-90,707
| -2% | -$15.3M | 0.01% | 803 |
|
|
2024
Q4 | $632M | Buy |
4,033,872
+40,749
| +1% | +$7.23M | 0.01% | 932 |
|
|
2024
Q3 | $727M | Buy |
3,993,123
+45,278
| +1% | +$8.73M | 0.02% | 819 |
|
|
2024
Q2 | $725M | Buy |
3,947,845
+2,142,466
| +119% | +$360M | 0.02% | 764 |
|
|
2024
Q1 | $321M | Sell |
1,805,379
-4,168
| -0.2% | -$579K | 0.01% | 1320 |
|
|
2023
Q4 | $224M | Buy |
1,809,547
+107,303
| +6% | +$11.9M | 0.01% | 1577 |
|
|
2023
Q3 | $197M | Buy |
1,702,244
+68,970
| +4% | +$8.41M | 0.01% | 1557 |
|
|
2023
Q2 | $192M | Sell |
1,633,274
-82,821
| -5% | -$8.46M | 0.01% | 1612 |
|
|
2023
Q1 | $137M | Buy |
1,716,095
+16,499
| +1% | +$1.3M | ﹤0.01% | 1819 |
|
|
2022
Q4 | $135M | Buy |
1,699,596
+134,291
| +9% | +$9.97M | ﹤0.01% | 1805 |
|
|
2022
Q3 | $109M | Sell |
1,565,305
-136,017
| -8% | -$9.83M | ﹤0.01% | 1902 |
|
|
2022
Q2 | $112M | Buy |
1,701,322
+17,811
| +1% | +$1.11M | ﹤0.01% | 1938 |
|
|
2022
Q1 | $112M | Buy |
1,683,511
+78,015
| +5% | +$4.87M | ﹤0.01% | 2071 |
|
|
2021
Q4 | $112M | Buy |
1,605,496
+64,110
| +4% | +$3.73M | ﹤0.01% | 2143 |
|
|
2021
Q3 | $80.5M | Buy |
1,541,386
+9,040
| +0.6% | +$535K | ﹤0.01% | 2346 |
|
|
2021
Q2 | $104M | Buy |
1,532,346
+51,718
| +3% | +$3.61M | ﹤0.01% | 2215 |
|
|
2021
Q1 | $114M | Buy |
1,480,628
+73,280
| +5% | +$5.33M | ﹤0.01% | 2118 |
|
|
2020
Q4 | $84.4M | Buy |
1,407,348
+210,428
| +18% | +$10.5M | ﹤0.01% | 2176 |
|
|
2020
Q3 | $51.5M | Buy |
1,196,920
+87,936
| +8% | +$3.82M | ﹤0.01% | 2281 |
|
|
2020
Q2 | $45.9M | Buy |
1,108,984
+282,219
| +34% | +$13.6M | ﹤0.01% | 2301 |
|
|
2020
Q1 | $35.8M | Buy |
826,765
+73,935
| +10% | +$3.87M | ﹤0.01% | 2273 |
|
|
2019
Q4 | $41.7M | Buy |
752,830
+1,201
| +0.2% | +$58.9K | ﹤0.01% | 2479 |
|
|
2019
Q3 | $26.1M | Buy |
751,629
+150,115
| +25% | +$6.71M | ﹤0.01% | 2667 |
|
|
2019
Q2 | $24.2M | Buy |
601,514
+546,317
| +990% | +$17.9M | ﹤0.01% | 2742 |
|
|
2019
Q1 | $1.82M | Buy |
55,197
+36,040
| +188% | +$850K | ﹤0.01% | 3741 |
|
|
2018
Q4 | $398K | Buy |
19,157
+5,568
| +41% | +$117K | ﹤0.01% | 4109 |
|
|
2018
Q3 | $239K | Buy |
13,589
+549
| +4% | +$9.21K | ﹤0.01% | 4277 |
|
|
2018
Q2 | $194K | Buy |
13,040
+5,607
| +75% | +$63.1K | ﹤0.01% | 4308 |
|
|
2018
Q1 | $75K | Buy |
7,433
+6,636
| +833% | +$65.4K | ﹤0.01% | 4383 |
|
|
2017
Q4 | $8K | Buy |
+797
| New | +$7.99K | ﹤0.01% | 4662 |
|
Other funds holding KRYS
ACA
SCM
HRCM
BlackRock's KRYS Position: Q2 2026 in Review
BlackRock increased its Krystal Biotech (KRYS) stake by 6.1% in Q2 2026, buying an estimated $72M and bringing the position to 4,181,432 shares worth $1.55B. The position accounts for 0.02% of the portfolio, ranked #535.
BlackRock first reported a position in KRYS in Q4 2017 and has held it in 35 quarters since. 422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- BlackRock held 4,181,432 shares of Krystal Biotech worth $1.55B as of Q2 2026.
- BlackRock bought 240,976 Krystal Biotech shares in Q2 2026, an estimated $72M.
- Krystal Biotech made up 0.02% of BlackRock's portfolio in Q2 2026, its #535 holding.
- BlackRock first reported a position in Krystal Biotech in Q4 2017 and has held it in 35 quarters since.
- 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.